Sravan Kumar Emany
At a glance: Sravan Kumar Emany is CFO at Beam Therapeutics (BEAM). Their latest SEC Form 4, filed Jan 5, 2026, reported a sale of $171K. On file: 0 purchase lines ($0) and 1 sale line ($171K).
Disclosed holdings: about $1.6M of BEAM stock: 73,706 shares reported on their latest Form 4 (filed Jan 5, 2026), valued at the Nov 20, 2026 close of $21.12. This counts only BEAM shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Sravan Kumar Emany's InsiderPrint
3 trades from SEC Form 4 filings, 2023 to 2025, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $171K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (2)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Adrian T. DillonDirector · HQY · 97% match
- Enrique LoresCEO, President · HPQ · 96% match
- T. Michael GlennDirector · PNR · 96% match
- Stan W. ConnallyCOO · SO · 96% match
- Gregg PiontekCFO, President · NPKI · 96% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jan 5SEC | BEAMBeam Therapeutics Inc. | Sell Plan | 6,29473,706 held (−8%) | $27.10 | $171K | -22.1% |
- Sell
CFO Sravan Kumar Emany sold $171K of BEAM at $27.10 — pre-scheduled 10b5-1 plan sale.
Follow Sravan Kumar Emany
Get one email when Sravan Kumar Emany files a new purchase or sale. Free.
At most one email a day about Sravan Kumar Emany, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.